Evidence map›Paper›PMID 26261090›Full record

ArticleGlycobiology2015

A glycomic approach reveals a new mycobacterial polysaccharide.

Gérald Larrouy-Maumus, Martine Gilleron, Henrieta Skovierová, Sophie Zuberogoitia, Patrick J Brennan, Germain Puzo, Mary Jackson, Jérôme Nigou

Open access · bronzeAbstract read
In one paragraph

Article in Glycobiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Performance of direct detection ofMicrobiology spectrum · 2025
    Article
  2. Article
  3. Shotgun Bacterial Lipid A Analysis Using Routine MALDI-TOF Mass Spectrometry.Methods in molecular biology (Clifton, N.J.) · 2021
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Gérald Larrouy-MaumusCNRS, Institut de Pharmacologie et de Biologie Structurale (IPBS), UMR 5089 CNRS/Université Paul Sabatier, 205 route de Narbonne, BP 64182, F-31077 Toulouse Cedex 4, France Université de Toulouse, Université Paul Sabatier, IPBS, F-31077 Toulouse, France.
Martine GilleronCNRS, Institut de Pharmacologie et de Biologie Structurale (IPBS), UMR 5089 CNRS/Université Paul Sabatier, 205 route de Narbonne, BP 64182, F-31077 Toulouse Cedex 4, France Université de Toulouse, Université Paul Sabatier, IPBS, F-31077 Toulouse, France.
Henrieta SkovierováMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523-1682, USA.
Sophie ZuberogoitiaCNRS, Institut de Pharmacologie et de Biologie Structurale (IPBS), UMR 5089 CNRS/Université Paul Sabatier, 205 route de Narbonne, BP 64182, F-31077 Toulouse Cedex 4, France Université de Toulouse, Université Paul Sabatier, IPBS, F-31077 Toulouse, France.
Patrick J BrennanMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523-1682, USA.
Germain PuzoCNRS, Institut de Pharmacologie et de Biologie Structurale (IPBS), UMR 5089 CNRS/Université Paul Sabatier, 205 route de Narbonne, BP 64182, F-31077 Toulouse Cedex 4, France Université de Toulouse, Université Paul Sabatier, IPBS, F-31077 Toulouse, France.
Mary JacksonMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523-1682, USA.
Jérôme NigouCNRS, Institut de Pharmacologie et de Biologie Structurale (IPBS), UMR 5089 CNRS/Université Paul Sabatier, 205 route de Narbonne, BP 64182, F-31077 Toulouse Cedex 4, France Université de Toulouse, Université Paul Sabatier, IPBS, F-31077 Toulouse, France jerome.nigou@ipbs.fr.
Colorado State University · USInstitut de Pharmacologie et de Biologie Structurale · FRCentre National de la Recherche Scientifique · FRUniversité Fédérale de Toulouse Midi-Pyrénées · FRUniversité Toulouse III - Paul Sabatier · FR

Funding

Biogenesis of Lipoarabinomannan in MycobacteriaR01AI064798 · NIAID · COLORADO STATE UNIVERSITY-FORT COLLINS · PI JACKSON, MARY · 2005 to 2019
$5.4M
SURFACE ANTIGENS OF M LEPRAE AND OTHER MYCOBACTERIAR37AI018357 · NIAID · COLORADO STATE UNIVERSITY-FORT COLLINS · PI BRENNAN, PATRICK JOSEPH · 1988 to 2007
$2.7M
MYOCOBACTERIAL CELL WALL AND DRUG DISCOVERYR01AI018357 · NIAID · COLORADO STATE UNIVERSITY-FORT COLLINS · PI BRENNAN, PATRICK JOSEPH · 1998 to 2000
$421k
SPECIFIC ANTIGENS OF ATYPICAL MYCOBACTERIAR22AI018357 · NIAID · COLORADO STATE UNIVERSITY-FORT COLLINS · PI BRENNAN, PATRICK JOSEPH · 1985 to 1987
–
Medical Research Council MR/J006874/1NIAID NIH HHS AI018357NIAID NIH HHS AI064798NIAID NIH HHS R01 AI064798
6 · The paper itself

Abstract

Mycobacterium tuberculosis lipoarabinomannan (LAM) and biosynthetically related lipoglycans and glycans play an important role in host-pathogen interactions. Therefore, the elucidation of the complete biosynthetic pathways of these important molecules is expected to afford novel therapeutic targets. The characterization of biosynthetic enzymes and transporters involved in the formation and localization of these complex macromolecules in the bacterial cell envelope largely relies on genetic manipulation of mycobacteria and subsequent analyses of lipoglycan structural alterations. However, lipoglycans are present in relatively low amounts. Their purification to homogeneity remains tedious and time-consuming. To overcome these issues and to reduce the biomass and time required for lipoglycan purification, we report here the development of a methodology to efficiently purify lipoglycans by sodium deoxycholate-polyacrylamide gel electrophoresis. This faster purification method can be applied on a small amount of mycobacterial cells biomass (10-50 mg), resulting in tens of micrograms of purified lipoglycans. This amount of purified products was found to be sufficient to undertake structural analyses of lipoglycans and glycans carbohydrate domains by a combination of highly sensitive analytical procedures, involving cryoprobe NMR analysis of intact macromolecules and chemical degradations monitored by gas chromatography and capillary electrophoresis. This glycomic approach was successfully applied to the purification and structural characterization of a newly identified polysaccharide, structurally related to LAM, in the model fast-growing species Mycobacterium smegmatis.

Indexed as

GlycomicsLipopolysaccharidesMycobacterium tuberculosisPolysaccharides, BacteriallipoarabinomannanLipopolysaccharidesPolysaccharides, BacterialglycomicMycobacteriumpolysaccharide

Identifiers

PMID26261090
PMCPMC4594620
OpenAlexW1920331222

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.